Swedish Orphan Biovitrum AB (publ)
STO:SOBI

Watchlist Manager
Swedish Orphan Biovitrum AB (publ) Logo
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Watchlist
Price: 290 SEK -0.21% Market Closed
Market Cap: 99.8B SEK
Have any thoughts about
Swedish Orphan Biovitrum AB (publ)?
Write Note

Swedish Orphan Biovitrum AB (publ)
Free Cash Flow

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Swedish Orphan Biovitrum AB (publ)
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Free Cash Flow
kr3.3B
CAGR 3-Years
32%
CAGR 5-Years
N/A
CAGR 10-Years
38%
Biogaia AB
STO:BIOG B
Free Cash Flow
kr377.4m
CAGR 3-Years
23%
CAGR 5-Years
17%
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Free Cash Flow
-kr3m
CAGR 3-Years
68%
CAGR 5-Years
56%
CAGR 10-Years
N/A
Vitrolife AB
STO:VITR
Free Cash Flow
kr655m
CAGR 3-Years
8%
CAGR 5-Years
14%
CAGR 10-Years
16%
Probi AB
STO:PROB
Free Cash Flow
kr29.7m
CAGR 3-Years
-43%
CAGR 5-Years
-25%
CAGR 10-Years
8%
BioArctic AB
STO:BIOA B
Free Cash Flow
kr302.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Swedish Orphan Biovitrum AB (publ)
Glance View

Market Cap
99.6B SEK
Industry
Biotechnology

Swedish Orphan Biovitrum AB (publ), often referred to as Sobi, is a biopharmaceutical company that has carved a niche in the development and commercialization of innovative treatments for rare diseases, primarily focusing on hematology, immunology, and specialty care. Founded in 2001 and headquartered in Stockholm, Sobi has garnered a reputation for its commitment to improving the lives of patients with complex medical conditions. The company's portfolio includes several key products that address unmet medical needs, particularly in areas such as hemophilia and other inherited disorders. Through strategic partnerships and acquisitions, Sobi has expanded its capabilities, bolstering its research and development pipeline while strengthening its market presence across Europe, North America, and beyond. As an investor, Sobi presents a compelling opportunity in the growing field of rare diseases, bolstered by a robust regulatory framework that often allows for expedited approval processes for groundbreaking therapies. The company’s focus on precision medicine and its dedication to patient-centric care position it well in an industry characterized by high demand and limited competition. With a solid financial foundation and a proactive approach to innovation, Sobi is poised to capture significant market share in a rapidly evolving landscape. Furthermore, with its strategic initiatives in expanding global reach and investing in next-generation therapies, Sobi exemplifies the principles of value investing by aligning long-term growth potential with the increasing need for specialized medical treatments.

SOBI Intrinsic Value
368.27 SEK
Undervaluation 21%
Intrinsic Value
Price

See Also

What is Swedish Orphan Biovitrum AB (publ)'s Free Cash Flow?
Free Cash Flow
3.3B SEK

Based on the financial report for Sep 30, 2024, Swedish Orphan Biovitrum AB (publ)'s Free Cash Flow amounts to 3.3B SEK.

What is Swedish Orphan Biovitrum AB (publ)'s Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
38%

Over the last year, the Free Cash Flow growth was 394%. The average annual Free Cash Flow growth rates for Swedish Orphan Biovitrum AB (publ) have been 32% over the past three years , and 38% over the past ten years .

Back to Top